Home > Analytics > SAMRAT PHARMACHEM

SAMRAT PHARMACHEM
Intrinsic Value | Fundamental Analysis

BOM : 530125     NSE :     
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward
Pledged Shares : NA
Dec 06,2024
Price(EOD): ₹ 405.35
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 125.66 Cr
Value of ₹ 1 Lac invested in SAMRAT PHARMACHEM
on Dec 06,2019 (price: ₹ 94.00)

₹ 1 L

₹ 4.31 L

1W : 1.3% 1M : -15.2% 1Y : 14.5%
COMMUNITY POLL
for SAMRAT PHARMACHEM
Please provide your vote to see the results
SAMRAT PHARMACHEM is part of below Screeners ↓
Best Quarterly Growth Small Cap Stocks
Industry Peers & Returns1W1M1Y
SAMRAT PHARMACHEM 1.3% -15.2% 14.5%
SUN PHARMACEUTICAL INDUSTRIES -0.2% 0.1% 47%
CIPLA -2% -7.7% 23.2%
DR REDDYS LABORATORIES 2.6% -1.5% 7.9%
ZYDUS LIFESCIENCES 2.1% 0.6% 54.5%
DIVIS LABORATORIES -1.9% 5.5% 60.6%
MANKIND PHARMA -1.2% -4.8% 36.6%
TORRENT PHARMACEUTICALS -0.2% 4.6% 57.8%
LUPIN 3.1% -2.2% 68.7%

FUNDAMENTAL ANALYSIS OF SAMRAT PHARMACHEM

 
Fundamentals Score
[ Q(TTM): Sep2024, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF SAMRAT PHARMACHEM

 
Valuation Score
[As on : Dec 06,2024 ]

Ratio Standalone
P/E
P/B
P/S
19.37
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 6.47 Cr
[Latest Qtr - Sep2024 - Standalone Results ]

1.93
P/B Calculated based on Book Value of Rs 65.00 Cr
[Latest Year - Mar2024 - Standalone Results ]

0.42
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Sep2024 - Standalone Results ]

Financial Ratios →

Insights 💡 There are potential 8% undervalued companies ! Discover More →

FAIR VALUE OF SAMRAT PHARMACHEM

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
-16%
51%
62%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF SAMRAT PHARMACHEM



SAMRAT PHARMACHEM vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF SAMRAT PHARMACHEM

Year Debt/Equity ratio
Standalone Consolidated
2024
2023
2022
Avg_3yrs
0.13
0.3
0.16
0.2
-
-
-
-
[Last Annual Data : Mar2024]
Financial Ratios →

PLEDGED PROMOTER SHARES OF SAMRAT PHARMACHEM

Pledged Promoter Shares
NA

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF SAMRAT PHARMACHEM

Standalone Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
-13.18%
29.99%
24.84%
28.86%
-12%
1347.84%
1384.39%
1507.94%
QtrlyTrend
4
Latest Qtr: Sep2024
Quarterly Result Analysis →

Insights 💡 SAMRAT PHARMACHEM is one of the top 47% companies with good quarterly result uptrend ! Discover More →

SAMRAT PHARMACHEM related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about SAMRAT PHARMACHEM


Is SAMRAT PHARMACHEM good for long term investment?

As on Dec 06,2024, the Fundamentals of SAMRAT PHARMACHEM look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of SAMRAT PHARMACHEM . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is SAMRAT PHARMACHEM UnderValued or OverValued?

As on Dec 06,2024, SAMRAT PHARMACHEM is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of SAMRAT PHARMACHEM ?

As on Dec 06,2024, the Intrinsic Value of SAMRAT PHARMACHEM is Rs. 268.20 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 484.61
Fair Value [Median EV / Sales Model] : Rs. 268.20
Fair Value [Median Price / Sales Model] : Rs. 250.81
Estimated Median Fair Value of SAMRAT PHARMACHEM : Rs. 268.20

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is SAMRAT PHARMACHEM trading at a Premium or Discount?

As on Dec 06,2024, SAMRAT PHARMACHEM is trading at a Premium of 51% based on the estimates of Median Intrinsic Value!